SCHEMBL2198208

SCHEMBL2198208

COCCOCC(=O)Nc1ccc(C)c(C(=O)c2ccc(Nc3ccc(F)cc3F)cc2Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 7/20 0.52
MAPK12 P53778 7/20 0.52
MAPK11 Q15759 7/20 0.52
MAPK14 Q16539 7/20 0.52
HPGD P15428 2/20 0.45
ALDH1A1 P00352 2/20 0.44
AVPR2 P30518 1/20 0.42
OXTR P30559 1/20 0.42
AVPR1A P37288 1/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
GBA1 P04062 1/20 0.39
HTT P42858 1/20 0.39
PPARG P37231 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2198811 0.90 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14HPGD
SCHEMBL2200097 0.85 MAPK13 (0.59) MAPK13MAPK12MAPK11MAPK14AVPR2
SCHEMBL2199162 0.84 MAPK13 (0.57) MAPK13MAPK12MAPK11MAPK14AVPR2
SCHEMBL2200533 0.82 MAPK14 (0.61) MAPK13MAPK12MAPK11MAPK14HPGD
SCHEMBL2198486 0.81 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14ALDH1A1
SCHEMBL2197746 0.81 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14AVPR2
SCHEMBL2196197 0.81 MAPK14 (0.53) MAPK13MAPK12MAPK11MAPK14AVPR2
SCHEMBL2574702 0.81 MAPK13 (0.49) MAPK13MAPK12MAPK11MAPK14AVPR2
SCHEMBL2199250 0.80 NPC1 (0.59) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2197594 0.80 MAPK13 (0.61) MAPK13MAPK12MAPK11MAPK14AVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP claimed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US claimed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP claimed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US claimed
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.